0001193125-23-251935.txt : 20231006 0001193125-23-251935.hdr.sgml : 20231006 20231006070758 ACCESSION NUMBER: 0001193125-23-251935 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231004 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231006 DATE AS OF CHANGE: 20231006 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Akili, Inc. CENTRAL INDEX KEY: 0001850266 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 981586159 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40558 FILM NUMBER: 231312589 BUSINESS ADDRESS: STREET 1: 125 BROAD STREET, 5TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617-456-0597 MAIL ADDRESS: STREET 1: 125 BROAD STREET, 5TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 FORMER COMPANY: FORMER CONFORMED NAME: Social Capital Suvretta Holdings Corp. I DATE OF NAME CHANGE: 20210310 8-K 1 d852809d8k.htm 8-K 8-K
NASDAQ false 0001850266 0001850266 2023-10-04 2023-10-04

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

October 6, 2023 (October 4, 2023)

 

 

Akili, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40558   92-3654772

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

125 Broad Street, Fifth Floor,

Boston, MA

   02110
(Address of Principal Executive Offices)   (Zip Code)

(617) 456-0597

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common stock, par value $0.0001 per share   AKLI   Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Board Chair and CEO Leadership Transition; Director Resignation

Effective October 5, 2023 (the “Transition Date”), the Board of Directors (the “Board”) of Akili, Inc. (the “Company”) approved a leadership transition of W. Edward Martucci II, Ph.D., one of the Company’s co-founders, from Chief Executive Officer of the Company to Chair of the Board and an advisor to the Company, and the appointment of Matthew Franklin, the Company’s President and Chief Operating Officer, to President and Chief Executive Officer and principal executive officer of the Company, effective as of the Transition Date.

On the Transition Date, the Board also elected Mr. Franklin as a member of the Board, effective as of the Transition Date, filling the director vacancy resulting from Chamath Palihapitiya’s resignation from the Board (and from his role as Chair of the Board). Mr. Palihapitiya informed the Board of his resignation, effective immediately, on October 4, 2023 and his resignation was not due to any disagreement with the Company.

Mr. Franklin will serve as a Class III director on the Board, and his initial term as a director will expire at the Company’s 2025 annual meeting of stockholders. As an executive officer of the Company, Mr. Franklin is not independent under the Nasdaq Marketplace Rules and the Company’s criteria for determining director independence.

Mr. Franklin, 50, served as our President and Chief Operating Officer from August 2022 to the Transition Date. Mr. Franklin served in the same capacity at legacy Akili from June 2022 until August 2022. Prior to joining us, from January 2021 to June 2022, Mr. Franklin served as General Manager of the Precision Oncology business unit at Exact Sciences Corp., a publicly traded molecular diagnostics company. From March 2020 to January 2021, Mr. Franklin served as Chief Commercial Officer of Thrive Earlier Detection Corp., a healthcare company, where he led the go-to-market strategy development for their multi-cancer early detection assay. From August 2018 to January 2020, Mr. Franklin served as Chief Business Officer of ArcherDX Inc., a growth-stage molecular diagnostics company, where he was responsible for establishing and scaling the global sales, customer support, marketing, market access, business development and corporate development teams. From March 2015 to July 2018, Mr. Franklin served as Senior Vice President of Global Marketing and Clinical Product Strategy of Foundation Medicine Inc., a molecular insights company which was acquired by Roche Holdings, Inc. in 2018. Mr. Franklin holds a B.A. in English Literature from Northwestern University and an MBA from the University of Michigan, Ann Arbor.

There are no arrangements or understandings between Mr. Franklin and any other person pursuant to which he was selected as a director of the Company. Mr. Franklin previously entered into an indemnification agreement on the Company’s standard form, a copy of which was filed with the Securities and Exchange Commission (the “SEC”) as Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-40558) on August 23, 2022. Other than Mr. Franklin’s employment arrangement with the Company, there have been no related party transactions between the Company and Mr. Franklin that would be reportable under Item 404(a) of Regulation S-K. Mr. Franklin has no family relationship with any of the executive officers or directors of the Company. As an executive of the Company, Mr. Franklin will not be eligible for any additional compensation as part of his service as a director.

Franklin Employment Arrangement

In connection with Mr. Franklin’s appointment as the Company’s President and Chief Executive Officer, Mr. Franklin will receive an annual base salary of $550,000 and will be eligible for an annual target bonus opportunity equal to 60% of his annual base salary, each effective as of the Transition Date.

In addition, the Board approved a grant to Mr. Franklin, effective as of October 12, 2023 (the “Option Grant Date”), of a stock option to purchase up to 1,057,180 shares (the “Option”) of common stock of the Company (“Common Stock”) at an exercise price equal to the closing price of the Common Stock on the Nasdaq Capital Market on the Option Grant Date. The shares of Common Stock underlying the Option will vest in eight (8) equal semiannual installments over a four (4)-year period following the Option Grant Date, subject to Mr. Franklin’s continued service on each such vesting date.

Mr. Franklin is also eligible for severance benefits under the Company’s Amended and Restated Executive Severance Plan (the “Severance Plan”). Under the Severance Plan, if the Company terminates Mr. Franklin’s employment without “cause” or if Mr. Franklin resigns from his employment with the Company for “good reason” (each as defined in the Severance Plan) prior to or more than 12 months following a change in control (as detailed in the Severance Plan), he will be entitled to receive (i) an amount equal to his monthly base salary multiplied by 12 plus (ii) an amount equal to the monthly employer COBRA premium for the same level group health coverage in effect on the date of termination for 12 months following the date of such termination (subject to his continued eligibility for such COBRA coverage as detailed in the Severance Plan). If the Company terminates Mr. Franklin’s employment without “cause” or he resigns from his employment with the Company for “good reason” within the “change in control period (as defined in the Severance Plan), he will be entitled to receive (a) his monthly base salary multiplied by 18 plus (b) 1.5 times his target bonus opportunity plus (c) an amount equal to the monthly employer COBRA premium for the same level group health coverage as in effect for Mr. Franklin on the date of termination for 18 months following the date of such termination (subject to his continued eligibility for such COBRA coverage as detailed in the Severance Plan) plus (d) for all outstanding and unvested equity awards of the Company that are subject to time-based vesting held by Mr. Franklin, full accelerated vesting of such awards.

Martucci Advisor Arrangement

In addition to assuming the role of Chair of the Board, Dr. Martucci has agreed to assist the Company in an advisory capacity for one (1) year from the Transition Date under the terms of an advisor agreement entered into with the Company on October 5, 2023 (the “Advisor Agreement”) that became effective as of the Transition Date. Pursuant to the Advisor Agreement, Dr. Martucci will receive (i) a monthly fee of $46,785 per month in exchange for approximately 40 hours of mutually agreed services per week through December 31, 2023 and (ii) $500 per hour for mutually agreed services beginning January 1, 2024 through October 5, 2024. As part of the Advisor Agreement, and notwithstanding his continued service to the Company, Dr. Martucci has agreed to forfeit seventy-five percent (75%) of his November 2, 2022 grant of performance-based restricted stock units. Dr. Martucci’s outstanding equity awards following the aforementioned forfeiture shall continue to vest in accordance with their terms. The Advisor Agreement is subject to Dr. Martucci’s execution and non-revocation of a standard release of claims.

Amendment to Non-Employee Director Compensation Policy

On August 2, 2023, the Board approved an amendment to the Company’s Non-Employee Director Compensation Policy (the “Director Compensation Policy”) to (i) provide that equity awards granted to directors annually as of the date of the Company’s annual meeting of stockholders, starting with the Company’s 2024 annual meeting of stockholders, shall be prorated based on the number of days of services on the Board as of the grant date of such first annual equity award to any directors who are not employees or officers of the Company or its subsidiaries (“Outside Directors”) and (ii) provide that, effective as of May 3, 2023, Outside Directors are eligible to receive cash and equity compensation under the Director Compensation Policy.

Martucci Director Compensation

From and after October 6, 2023 (i.e. the day after the Transition Date), and for so long as Dr. Martucci remains a non-employee member of the Board, Dr. Martucci will be eligible for cash and equity compensation for his service as an Outside Director on the Board and as non-executive Chair of the Board (as applicable), pursuant to the terms of the Director Compensation Policy.

The foregoing descriptions of the Severance Plan, Dr. Martucci’s Advisor Agreement and the Director Compensation Policy do not purport to be complete and are qualified in their entirety by reference to the Advisor Agreement and Director Compensation Policy, copies of which will be filed with the SEC in the Company’s Quarterly Report on Form 10-Q for the three months ended September 30, 2023, and the Severance Plan, a copy of which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on October 27, 2022 (File No. 001-40558).

Item 7.01

Regulation FD Disclosure

On October 6, 2023, the Company issued a press release announcing the leadership transition detailed above in Item 5.02 of this Current Report on Form 8-K. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1, is being “furnished” and shall not be deemed “filed” with the SEC for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

No.

    Description of Exhibit
99.1    Press Release issued by Akili, Inc. on October 6, 2023
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

Forward-Looking Statements

This Current Report on Form 8-K and the accompanying exhibit contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking statements include, without limitation, statements in this Current Report on Form 8-K and the accompanying exhibit related to: the Company’s recently-announced business strategy and plans to transition to a non-prescription model; the Company’s plans to explore opportunities and to drive success and value for shareholders; and the Company’s expectations regarding its ability to increase patient access to its treatments and to remove friction for customers by reducing its reliance on intermediaries. Any forward-looking statements in this Current Report on Form 8-K and the accompanying exhibit are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Current Report on Form 8-K and the accompanying exhibit, including, without limitation, risks and uncertainties related to: the Company’s ability to successfully navigate the leadership transition; the Company’s ability to successfully further commercialize and obtain approval from FDA for EndeavorOTC; the Company’s ability to successfully create, and navigate, a new category of medicine and to achieve broad adoption of digital therapeutics among healthcare providers, caregivers, and patients; the Company’s ability to successfully commercialize and support its EndeavorRx prescription product and to obtain further FDA approval to successfully convert its EndeavorRx product to an over-the-counter product; the Company’s ability to defend its intellectual property and satisfy various FDA and other regulatory requirements in and outside of the United States; the risk of downturns and a changing regulatory landscape in the highly competitive industry in which the Company operates; the timing and results expected from the Company’s and its partners’ clinical trials and its reliance on third parties for certain aspects of its business; the Company’s ability to accurately estimate expenses, capital requirements, and needs for additional financing; and other risks identified in the Company’s current filings and any subsequent filings made with the Securities and Exchange Commission (SEC). The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof and should not be relied upon as representing the Company’s views as of any subsequent date. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Akili, Inc.
By:  

/s/ Santosh Shanbhag

Name:   Santosh Shanbhag
Title:   Chief Financial Officer

Date: October 6, 2023

EX-99.1 2 d852809dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

LOGO

Akili Announces Leadership Transition

Co-founder and CEO Eddie Martucci, Ph.D. transitions to role of Board chair; Matt Franklin, president and chief operating officer of Akili, appointed president and chief executive officer

BOSTON – October 6, 2023 – Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that Eddie Martucci transitioned to the role of Board chair, and Matt Franklin has been appointed to serve as president and CEO of the company and as a member of its board of directors, effective October 5, 2023. Martucci replaces former Board chair, Chamath Palihapitiya, who has resigned from the Board, effective October 4, 2023.

The leadership transition follows the company’s announcement in September that it plans to shift from a prescription to a non-prescription business model. As the company progresses into this next critical phase, building on the vision and culture of innovation established by Martucci, Franklin’s leadership will bring significant expertise establishing and scaling robust and cost-effective business models, effectively implementing creative marketing and partnering strategies, and focusing on revenue growth and profitability.

“From day one, Akili’s brand has been about establishing medical credibility and constantly innovating to bring a new class of products to patients. Matt excels at advancing both of these value drivers in innovative models and was the spearhead of our recent business model shift. His stepping into the role of CEO comes at an optimal time, as Akili focuses on executing this new strategy to bring our bold vision to life for millions of patients seeking better cognitive and mental health solutions,” said Martucci. “Akili’s transition to a non-prescription business is a springboard to transform the company and remove friction for the customers we serve. I look forward to collaborating with Matt and the leadership team to explore and execute opportunities to drive success and value for shareholders in this next phase of the company.”

“I am honored to have the opportunity to continue to work with Eddie and the rest of the Board in my new role and to support Akili’s mission of helping millions of people living with cognitive impairments,” said Franklin. “Akili’s journey ahead will continue to be shaped by our innovation and commitment to challenging and redefining the status quo. I strongly believe that there is a monumental opportunity for Akili to revolutionize the medical industry by bringing clinically validated, consumer-focused treatments directly to those who suffer from these chronic conditions, to improve their cognitive function and enhance their daily lives.”

Martucci co-founded Akili in 2011 with a vision to transform the design, delivery and experience of cognitive medicine. He was the COO until August 2015 and has been the sole CEO since that time. Under his leadership, Akili realized the initial phase of its vision, introducing the world’s first and only clinically validated FDA-authorized video game treatment. With his transition to the role of Board chair, Martucci replaced Palihapitiya who served as chair of the Board since investing in the company and facilitating its transition to a public listing in August 2022.

Franklin joined Akili in June 2022 as its president and chief operating officer. He has a proven track record leading early commercialization and growing disruptive healthcare business models in the medical device and diagnostics industries for leading companies such as Boston Scientific, Foundation Medicine, Thrive Earlier Detection and Exact Sciences. As a part of these organizations, Franklin also gained experience in mergers and acquisitions, as both the strategist and the acquisition target. Since joining Akili, Franklin has implemented metrics-driven performance improvements and enhanced operational efficiency at Akili including growth of EndeavorRx®, which has now been prescribed in every state in the U.S., guided the company’s launch of its non-prescription adult ADHD product, EndeavorOTCTM, under FDA guidance, and championed the plan to move the business to a non-prescription model.

EndeavorOTC Indication and Overview

EndeavorOTC is a digital therapeutic indicated to improve attention function, ADHD symptoms and quality of life in adults 18 years of age and older with primarily inattentive or combined-type ADHD. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx, a prescription digital therapeutic indicated to improve attention function in children ages 8-12. EndeavorOTC is available under the U.S. Food and Drug Administration’s current Enforcement Policy for Digital Health Devices for Treating Psychiatric Disorders During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency. EndeavorOTC has not been cleared or authorized by the U.S. Food and Drug Administration for its indications. It is recommended that patients speak to their health care provider before starting EndeavorOTC treatment. No serious adverse events have been reported in any of our clinical studies. To learn more, visit EndeavorOTC.com.

EndeavorRx Indication and Overview

EndeavorRx is the first-and-only FDA-authorized treatment delivered through a video game experience. EndeavorRx is indicated to improve attention function as measured by computer-based testing in children ages 8 to 12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure Test of Variables of Attention (TOVA®) of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder. EndeavorRx is available by prescription only. It is not intended to be used as a stand-alone therapeutic and is not a substitution for a child’s medication. The most common side effect observed in children in EndeavorRx’s

clinical trials was a feeling of frustration, as the game can be quite challenging at times. No serious adverse events were associated with its use. EndeavorRx is recommended to be used for approximately 25 minutes a day, 5 days a week, over initially at least 4 consecutive weeks, or as recommended by your child’s health care provider. To learn more about EndeavorRx, please visit EndeavorRx.com.

About Akili

Akili is pioneering the development of cognitive treatments through game-changing technologies. Akili’s approach of leveraging technologies designed to directly target the brain establishes a new category of medicine – medicine that is validated through clinical trials like a drug or medical device but experienced like entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical programs. Driven by Akili’s belief that effective medicine can also be fun and engaging, Akili’s products are delivered through captivating action video game experiences. For more information, please visit www.akiliinteractive.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking statements include, without limitation, statements in this press release related to: the Company’s recently-announced business strategy and plans to transition to a non-prescription model; the Company’s plans to explore opportunities and to drive success and value for shareholders; and the Company’s expectations regarding its ability to increase patient access to its treatments and to remove friction for customers by reducing its reliance on intermediaries. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to: the Company’s ability to successfully navigate the leadership transition; the Company’s ability to successfully further commercialize and obtain approval from FDA for EndeavorOTC; the Company’s ability to successfully create, and navigate, a new category of medicine and to achieve broad adoption of digital therapeutics among healthcare providers, caregivers, and patients; the Company’s ability to successfully commercialize and support its EndeavorRx prescription product and to obtain further FDA approval to successfully convert its EndeavorRx product to an over-the-counter product; the Company’s ability to defend its intellectual property and satisfy various FDA and other regulatory requirements in and outside of the United States; the risk of downturns and a changing regulatory landscape in the highly competitive industry in which the Company operates; the timing and

results expected from the Company’s and its partners’ clinical trials and its reliance on third parties for certain aspects of its business; the Company’s ability to accurately estimate expenses, capital requirements, and needs for additional financing; and other risks identified in the Company’s current filings and any subsequent filings made with the Securities and Exchange Commission (SEC). The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof and should not be relied upon as representing the Company’s views as of any subsequent date. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

CONTACTS

Investors:

Santosh Shanbhag

Chief Financial Officer

InvestorRelations@akiliinteractive.com

Media:

Julie DiCarlo

Communications

julie@akiliinteractive.com

###

EX-101.SCH 3 akli-20231004.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 akli-20231004_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 akli-20231004_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g852809g1006042319924.jpg GRAPHIC begin 644 g852809g1006042319924.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Oct. 04, 2023
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001850266
Document Type 8-K
Document Period End Date Oct. 04, 2023
Entity Registrant Name Akili, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-40558
Entity Tax Identification Number 92-3654772
Entity Address, Address Line One 125 Broad Street
Entity Address, Address Line Two Fifth Floor
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02110
City Area Code (617)
Local Phone Number 456-0597
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.0001 per share
Trading Symbol AKLI
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 8 d852809d8k_htm.xml IDEA: XBRL DOCUMENT 0001850266 2023-10-04 2023-10-04 NASDAQ false 0001850266 8-K 2023-10-04 Akili, Inc. DE 001-40558 92-3654772 125 Broad Street Fifth Floor Boston MA 02110 (617) 456-0597 false false false false Common stock, par value $0.0001 per share AKLI true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports akli-20231004.xsd akli-20231004_lab.xml akli-20231004_pre.xml d852809d8k.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d852809d8k.htm": { "nsprefix": "akli", "nsuri": "http://www.akiliinteractive.com/20231004", "dts": { "schema": { "local": [ "akli-20231004.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] }, "labelLink": { "local": [ "akli-20231004_lab.xml" ] }, "presentationLink": { "local": [ "akli-20231004_pre.xml" ] }, "inline": { "local": [ "d852809d8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2022": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "report": { "R1": { "role": "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-10-04_to_2023-10-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d852809d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-10-04_to_2023-10-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d852809d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.akiliinteractive.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001193125-23-251935-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-251935-xbrl.zip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end